Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Leases (2023 - 2025)

Indivior Pharmaceuticals has reported Leases over the past 3 years, most recently at $26.0 million for Q4 2025.

  • Quarterly results put Leases at $26.0 million for Q4 2025, down 33.33% from a year ago — trailing twelve months through Dec 2025 was $26.0 million (down 33.33% YoY), and the annual figure for FY2025 was $26.0 million, down 33.33%.
  • Leases for Q4 2025 was $26.0 million at Indivior Pharmaceuticals, down from $30.0 million in the prior quarter.
  • Over the last five years, Leases for INDV hit a ceiling of $40.0 million in Q4 2023 and a floor of $26.0 million in Q4 2025.
  • Median Leases over the past 3 years was $36.0 million (2025), compared with a mean of $34.5 million.
  • Biggest five-year swings in Leases: decreased 2.5% in 2024 and later crashed 33.33% in 2025.
  • Indivior Pharmaceuticals' Leases stood at $40.0 million in 2023, then fell by 2.5% to $39.0 million in 2024, then tumbled by 33.33% to $26.0 million in 2025.
  • The last three reported values for Leases were $26.0 million (Q4 2025), $30.0 million (Q3 2025), and $35.0 million (Q2 2025) per Business Quant data.